Key points are not available for this paper at this time.
Design
Review
Should not yet alter lipid-lowering practice; leaves open research on residual risk, combination therapies, and personalized approaches.
Dyslipidemia has been globally recognized, for almost seven decades, as one of the most important risk factors for the development and complications of atherosclerotic cardiovascular disease (ASCVD) [...].
No takes yet. Share an insight, caveat, or question.
Fras et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: